Evofem Biosciences's revenue for the
three
months ended in Dec. 2023 was $4.84 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $18.22 Mil.
Evofem Biosciences's Revenue per Share for the
three
months ended in Dec. 2023 was $0.24.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $6.38.
Warning Sign:
Evofem Biosciences Inc revenue per share has been in decline over the past 3 years.
During the past 12 years, Evofem Biosciences's highest 3-Year average Revenue per Share Growth Rate was -88.50% per year. The lowest was -88.50% per year. And the median was -88.50% per year.
Evofem Biosciences Revenue Historical Data
The historical data trend for Evofem Biosciences's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Evofem Biosciences's Revenue
For the Biotechnology subindustry, Evofem Biosciences's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evofem Biosciences's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Revenue distribution charts can be found below:
* The bar in red indicates where Evofem Biosciences's Revenue falls into.
Evofem Biosciences Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Evofem Biosciences Revenue Related Terms
Thank you for viewing the detailed overview of Evofem Biosciences's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Evofem Biosciences (Evofem Biosciences) Business Description
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EVFM has been successfully added to your 